Evidence map›Paper›PMID 26984638›Full record

ArticleBMC biology2016

The role of the aryl hydrocarbon receptor in the development of cells with the molecular and functional characteristics of cancer stem-like cells.

Elizabeth A Stanford, Zhongyan Wang, Olga Novikov, Francesca Mulas, Esther Landesman-Bollag, Stefano Monti, Brenden W Smith, David C Seldin, George J Murphy, David H Sherr

Open access · goldAbstract read
In one paragraph

Article in BMC biology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers.

0numbers the graph read from it
0cells of the map it votes in
62citing papers in PubMed
4.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

62 citing papers in PubMed, 97 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Review

2 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Elizabeth A StanfordDepartment of Environmental Health, Boston University School of Public Health, 72 East Concord Street (R-408), Boston, Massachusetts, 02118, USA.
Zhongyan WangDepartment of Environmental Health, Boston University School of Public Health, 72 East Concord Street (R-408), Boston, Massachusetts, 02118, USA.
Olga NovikovDepartment of Environmental Health, Boston University School of Public Health, 72 East Concord Street (R-408), Boston, Massachusetts, 02118, USA.
Francesca MulasDepartment of Medicine, Boston University School of Medicine, Section of Computational Biomedicine, Boston, MA, 02118, USA.
Esther Landesman-BollagDepartment of Medicine, Boston University School of Medicine, Section of Hematology and Oncology, 650 Albany Street, Boston, MA, 02118, USA.
Stefano MontiDepartment of Medicine, Boston University School of Medicine, Section of Computational Biomedicine, Boston, MA, 02118, USA.
Brenden W SmithBoston University Molecular and Translational Medicine Program, 72 E. Concord Street, Boston, MA, 02118, USA.
David C SeldinDepartment of Medicine, Boston University School of Medicine, Section of Hematology and Oncology, 650 Albany Street, Boston, MA, 02118, USA.
George J MurphyDepartment of Medicine, Boston University School of Medicine, Section of Hematology and Oncology, 650 Albany Street, Boston, MA, 02118, USA.
David H SherrDepartment of Environmental Health, Boston University School of Public Health, 72 East Concord Street (R-408), Boston, Massachusetts, 02118, USA. dsherr@bu.edu.
Boston University · USBoston Medical Center · US

Funding

Training CoreP42ES007381 · NIEHS · BOSTON UNIVERSITY MEDICAL CAMPUS · PI SHERR, DAVID H · 1995 to 2019
$46.1M
Signaling Pathways in Stages of TumorigenesisP01ES011624 · NIEHS · TUFTS UNIVERSITY BOSTON · PI SONENSHEIN, GAIL E. · 2001 to 2012
$11.4M
NIEHS NIH HHS P01 ES011624NIEHS NIH HHS P42 ES007381NIEHS NIH HHS P42ES007381
6 · The paper itself

Abstract

backgroundSelf-renewing, chemoresistant breast cancer stem cells are believed to contribute significantly to cancer invasion, migration and patient relapse. Therefore, the identification of signaling pathways that regulate the acquisition of stem-like qualities is an important step towards understanding why patients relapse and towards development of novel therapeutics that specifically target cancer stem cell vulnerabilities. Recent studies identified a role for the aryl hydrocarbon receptor (AHR), an environmental carcinogen receptor implicated in cancer initiation, in normal tissue-specific stem cell self-renewal. These studies inspired the hypothesis that the AHR plays a role in the acquisition of cancer stem cell-like qualities.

resultsTo test this hypothesis, AHR activity in Hs578T triple negative and SUM149 inflammatory breast cancer cells were modulated with AHR ligands, shRNA or AHR-specific inhibitors, and phenotypic, genomic and functional stem cell-associated characteristics were evaluated. The data demonstrate that (1) ALDH(high) cells express elevated levels of Ahr and Cyp1b1 and Cyp1a1, AHR-driven genes, (2) AHR knockdown reduces ALDH activity by 80%, (3) AHR hyper-activation with several ligands, including environmental ligands, significantly increases ALDH1 activity, expression of stem cell- and invasion/migration-associated genes, and accelerates cell migration, (4) a significant correlation between Ahr or Cyp1b1 expression (as a surrogate marker for AHR activity) and expression of stem cell- and invasion/migration-associated gene sets is seen with genomic data obtained from 79 human breast cancer cell lines and over 1,850 primary human breast cancers, (5) the AHR interacts directly with Sox2, a master regulator of self-renewal; AHR ligands increase this interaction and nuclear SOX2 translocation, (6) AHR knockdown inhibits tumorsphere formation in low adherence conditions, (7) AHR inhibition blocks the rapid migration of ALDH(high) cells and reduces ALDH(high) cell chemoresistance, (8) ALDH(high) cells are highly efficient at initiating tumors in orthotopic xenografts, and (9) AHR knockdown inhibits tumor initiation and reduces tumor Aldh1a1, Sox2, and Cyp1b1 expression in vivo.

conclusionsThese data suggest that the AHR plays an important role in development of cells with cancer stem cell-like qualities and that environmental AHR ligands may exacerbate breast cancer by enhancing expression of these properties.

Indexed as

BreastBreast NeoplasmsCell Line, TumorCell MovementFemaleGene Expression Regulation, NeoplasticHumansNeoplastic Stem CellsReceptors, Aryl HydrocarbonReceptors, Aryl HydrocarbonAryl hydrocarbon receptorBreast cancerEnvironmentSox2Tumor initiating cells

Identifiers

PMID26984638
PMCPMC4794823
OpenAlexW2297079083

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.